Emerald raises £1.4m to expand preventative healthcare platform

A preventative healthcare professional looking at a laptop.

Emerald’s goal is to make preventative healthcare part of everyday life (Image: pexels/karola-g)

Preventative healthcare platform Emerald has secured £1.4 million in new funding, taking its total raised since launching in 2024 to £2.9 million.

The latest round includes a £700,000 grant from Innovate UK and £700,000 in venture capital investment. Existing investors backed the raise alongside new investors including Sequel and Highgoal.

Read the latest issue of WellNation

“There’s huge demand for access to simple healthcare tools that move beyond just testing,” explains Alexander Badalyan, Co-Founder and CEO of Emerald. “People want to understand what those results mean and the steps they can take to boost their long-term health – informed by guidance from trusted medical experts.

“A preventative approach to healthcare significantly improves long-term health outcomes by providing a more holistic view of a patient’s health, highlighting potential issues before they become critical, and empowering people to enter the right pathway earlier. 

“Achieving this ambition is a cornerstone of the current Government’s current health agenda – but the NHS cannot deliver this shift alone. Government efforts must be matched with innovative solutions that are able to have widespread reach.

“Emerald has unlocked access to millions of potential users through its partnerships – with ambitions to becomethe UK’s go-to platform for long-term health management. This additional funding allows us to build on the demand we’re already seeing, deepen these partnerships, and expand care.”

Emerald combines laboratory screening with a digital platform that brings together test results, wearable data and health history. Members are also paired with a GP who can diagnose, prescribe treatments and make referrals into private or NHS care where appropriate.

The clinician-founded business is Care Quality Commission registered and operates as a UKCA Class I medical device authorised with the MHRA.

Emerald said the new funding will support commercial growth, further development of its clinical services and expansion of its AI capabilities. The company aims to reach one million members over the next three years.

Demand has grown strongly during 2026, with Emerald increasing its member base tenfold and processing more than 100,000 laboratory tests.

The business has also expanded through partnerships with organisations including Pluxee, Epassi and Yonder, helping employers and other partners provide preventative screening and follow-up healthcare services.

Emerald said its long-term goal is to make preventative healthcare part of everyday life by giving people a more connected view of their health and helping them identify potential risks earlier.

Recommended Posts